Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults

Atherosclerosis

Volumn 231, Issue 1, 2013, Pages 114-119

  Jovanovich, Anna ^a   Ix, Joachim H ^b,c,d   Gottdiener, John ^e   McFann, Kim ^a   Katz, Ronit ^f   Kestenbaum, Bryan ^f   De Boer, Ian H ^f   Sarnak, Mark ^g   Shlipak, Michael G ^h   Mukamal, Kenneth J ⁱ   Siscovick, David ^f   Chonchol, Michel ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Fibroblast growth factor 23; Left ventricular hypertrophy; Left ventricular mass; Older adults

Indexed keywords

ALBUMIN; CREATININE; FIBROBLAST GROWTH FACTOR 23;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; RISK FACTOR;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; FIBROBLAST GROWTH FACTOR 23; LEFT VENTRICULAR HYPERTROPHY; LEFT VENTRICULAR MASS; OLDER ADULTS;

AGED; FEMALE; FIBROBLAST GROWTH FACTORS; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LONGITUDINAL STUDIES; MALE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84885439430     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.09.002     Document Type: Article

References (33)

1. Liu S., Quarles L.D. How fibroblast growth factor 23 works. JAm Soc Nephrol 2007 Jun, 18(6):1637-1647.
2. Isakova T., Xie H., Yang W., et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011 Jun 15, 305(23):2432-2439.
3. Fliser D., Kollerits B., Neyer U., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the MILD to Moderate Kidney Disease (MMKD) Study. JAm Soc Nephrol 2007 Sep, 18(9):2600-2608.
4. Ix J.H., Shlipak M.G., Wassel C.L., Whooley M.A. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 2010 Mar, 25(3):993-997.
5. Kendrick J., Cheung A.K., Kaufman J.S., et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. JAm Soc Nephrol 2011 Oct, 22(10):1913-1922.
6. Parker B.D., Schurgers L.J., Brandenburg V.M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix GIa protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010 May 10, 152(10):640-648.
7. Ix J.H., Katz R., Kestenbaum B.R., et al. Fibroblast growth Factor-23 and death, heart failure, and cardiovascular events in community-living Individuals: CHS (Cardiovascular Health Study). JAm Coll Cardiol 2012 Jul 17, 60(3):200-207.
8. Gutierrez O.M., Januzzi J.L., Isakova T., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009 May 19, 119(19):2545-2552.
9. Hsu H.J., Wu M.S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 2009 Feb, 337(20):116-122.
10. Mirza M.A., Larsson A., Melhus H., Lind L., Larsson T.E. Serum intact FGF23 associated with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009 Dec, 207(2):546-551.
11. Faul C., Amaral A.P., Oskouei B., et al. FGF23 induces left ventricular hypertrophy. JClin Invest 2011 Nov, 121(11):4393-4408.
12. Fried L.P., Borhani N.O., Enright P., et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991 Feb, 1(3):263-276.
13. Jonsson K.B., Zahradnik R., Larsson T., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. NEngl J Med 2003 Apr 24, 348(17):1656-1663.
14. Gardin J.M., Wong N.D., Bommer W., et al. Echocardiographic design of a multicenter investigation of free-living elderly subjects: the Cardiovascular Health Study. JAm Soc Echocardiogr 1992 Jan-Feb, 5(1):63-72.
15. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986 Feb 15, 57(6):450-458.
16. Rautaharju P.M., MacInnis P.J., Warren J.W., Wolf H.K., Ryers P.M., Calhoun H.P. Methodology of ECG interpretation in the Dalhousie program; NOVACODE ECG classification procedures for clinical trials and population health surveys. Methods Inf Med 1990 Sep, 29(4):362-374.
17. Rautaharju P.M., Calhoun H.P., Chaitman B.R. NOVACODE serial ECG classification system for clinical trials and epidemiologic studies. JElectrocardiol 1992, 24(Suppl.):179-187.
18. Rautaharju P.M., Park L.P., Gottdiener J.S., et al. Race- and sex-specific ECG models for left ventricular mass in older populations. Factors influencing overestimation of left ventricular hypertrophy prevalence by ECH criteria in African-Americans. JElectrocardiol 2000 Jul, 33(3):205-218.
19. Rautaharju P.M., Manolio T.A., Siscovick D., et al. Utility of new electrocardiographic models for left ventricular mass in older adults. The Cardiovascular Health Study Collaborative Research Group. Hypertension 1996 July, 28(1):8-15.
20. Cushman M., Arnold A.M., Psaty B.M., et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study. Circulation 2005 Jul 5, 112(1):25-31.
21. Shlipak M.G., Sarnak M.J., Katz R., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. NEngl J Med 2005 May 19, 352(20):2049-2060.
22. Stevens L.A., Coresh J., Schmid C.H., et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008 Mar, 51(3):395-406.
23. Urakawa I., Yamazaki Y., Shimada T., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006 Dec, 444(7120):770-774.
24. Shalhoub V., Shatzen E.M., Ward S.C., et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. JClin Invest 2012 Jul 2, 122(7):2543-2553.
25. Neves K.R., Graciolli F.G., dos Reis L.M., Pasqualacci C.A., Moyses R.M., Jorgetti V. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004 Dec, 66(6):2237-2244.
26. Galetta F., Cupisti A., Franzoni F., et al. Left ventricular function and calcium phosphate plasma levels in uraemic patients. JIntern Med 2005 Oct, 258(4):378-384.
27. de Borst M.H., Vervloet M.G., ter Wee P.M., Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. JAm Soc Nephrol 2011 Sep, 22(9):1603-1609.
28. Dai B., David V., Martin A., et al. Acomparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One 2012, 7(9):e444161.
29. Gurley S.B., Allred A., Thu L.E., et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. JClin Invest 2006 August 1, 116(8):2218-2225.
30. Dominguez J.R., Shlipak M.G., Whooley M.A., Ix J.H. Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. JAm Soc Nephrol 2013 Mar, 24(4):647-654.
31. Klapholz M., Maurer M., Lowe A.M., et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. JAm Coll Cardiol 2004 Apr 21, 43(8):1432-1438.
32. Melenovsky V., Borlaug B.A., Rosen B., et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. JAm Coll Cardiol 2007 Jan 16, 49(2):198-207.
33. Yancy C.W., Lopatin M., Stevenson L.W., DeMarco T., Fonarow G.C., ADHERE Scientific Advisory Committee and Investigators Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Hearth Failure National Registry (ADHERE) Database. JAm Coll Cardiol 2006 Jan 3, 47(1):76-84.